Skip to main content

Foundation Medicine Licenses Mutation Detection Technology From TwinStrand Biosciences

NEW YORK – Foundation Medicine said on Wednesday that it has signed a non-exclusive licensing agreement with TwinStrand Biosciences for a sequencing-based technology for rare mutation detection.

The agreement covers two foundational patent families from TwinStrand, a University of Washington spinout based in Seattle. 

The company's duplex sequencing technology independently tracks both strands of DNA molecules and then compares the paired sequences to eliminate errors. It can be used for residual cancer detection and genetic toxicology, among other applications. 

"We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration," Foundation Medicine CEO Cindy Perettie said in a statement.